
Built on an efficacy-first model, Spanios is harnessing the powerful capabilities of Patient Derived Tumoroids (PDTs) to accelerate next-gen drug development.
See the full profile
The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.
Send a short message. We’ll pass it to Spanios with your name and email, so they can reply.
Create an account or log in to send this request. Already a member? Log in
Introductions to innovators are open to innovators, investors, mentors and corporates.